Tokyo Tape
Sign in
← PeptiDream

Annual report

4587.TEDINET S100T61M
Period2023-01-01 → 2023-12-31
Filed2024-03-28
StandardIFRS
ConsolidatedYes
Data checks18 of 22 passed

Amended by S100UF9P (2024-09-25).

Key figures · 162
MetricValuePeriodScopeSource row
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥6.8bn2023-01-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥9.0bn2022-01-01 → 2022-12-31Cons.Operating profit loss IFRS
Ordinary income¥8.1bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥6.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥60.1bnat 2022-12-31Cons.Total assets (5-year summary)
Total assets¥27.0bnat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥30.5bnat 2022-12-31Cons.Net assets (5-year summary)
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥350m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.3bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥21.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥66m2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥51.132022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.962021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥311.16at 2023-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥234.8at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥246.63at 2022-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥195.1at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥168.1at 2020-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio81.4%at 2020-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE8.4%2023-01-01 → 2023-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE24.4%2022-01-01 → 2022-12-31Cons.Rate of return on equity (5-year summary)
ROE26.3%2022-01-01 → 2022-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE11.0%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees603at 2023-12-31Cons.Number of employees
Employees569at 2022-12-31Cons.Number of employees
Employees141at 2021-12-31dCons.Number of employees
Employees128at 2020-12-31dCons.Number of employees
Revenue¥12.7bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥15.4bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥9.4bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥11.7bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥1.0bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥7.2bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income¥6.4bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income¥9.1bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income¥6.4bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥8.8bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥4.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥7.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥707m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥3.8bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥7.0bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax¥6.9bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income¥5.8bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥4.3bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥3.6bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥4.4bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥488m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥2.8bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥68.2bnat 2023-12-31StandaloneAssets
Total assets¥55.2bnat 2022-12-31StandaloneAssets
Total assets¥26.6bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥26.3bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥17.8bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥20.0bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥27.6bnat 2023-12-31StandaloneLiabilities
Total liabilities¥25.8bnat 2022-12-31StandaloneLiabilities
Net assets / equity¥40.6bnat 2023-12-31StandaloneNet assets
Net assets / equity¥29.4bnat 2022-12-31StandaloneNet assets
Net assets / equity¥25.0bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥21.2bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥17.0bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥17.4bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥16.2bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥847mat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥11.7bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥7.1bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥7.0bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥6.9bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥242m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.5bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥138m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥66m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥237m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥29m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥44.852023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥33.112022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥27.982021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥35.42020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-3.92019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥22.422018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥27.782021-01-01 → 2021-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥34.262020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥21.332018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥312.89at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥226.48at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥192.39at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥168.1at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥134.97at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥138.73at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio59.5%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio53.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio93.8%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio94.8%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio86.6%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE16.6%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE15.8%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE15.6%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE23.4%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE17.3%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued130,010,400at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued125,910,400at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued125,310,400at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued125,310,400at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees153at 2023-12-31StandaloneNumber of employees
Employees155at 2022-12-31StandaloneNumber of employees
Employees141at 2021-12-31dStandaloneNumber of employees
Employees128at 2020-12-31dStandaloneNumber of employees
Employees107at 2019-12-31dStandaloneNumber of employees
Employees104at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-12-31−¥87m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-12-31−¥87m
Drug Discovery And Development Businessreportable segmentemployeesat 2023-12-31153 pure
Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥12.7bn
Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥12.7bn
Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-12-31¥6.4bn
Radiopharmaceuticals Businessreportable segmentemployeesat 2023-12-31450 pure
Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥16.1bn
Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥16.0bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥87m
Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-12-31¥475m
—segment totalrevenue2023-01-01 → 2023-12-31¥28.8bn
—segment totalrevenue external2023-01-01 → 2023-12-31¥28.7bn
—segment totalrevenue intersegment2023-01-01 → 2023-12-31¥87m
—segment totalsegment profit2023-01-01 → 2023-12-31¥6.9bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-12-31−¥27m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-12-31−¥27m
Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥15.4bn
Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥15.4bn
Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥9.2bn
Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥11.5bn
Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥11.4bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-12-31¥27m
Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥236m
—segment totalrevenue2022-01-01 → 2022-12-31¥26.9bn
—segment totalrevenue external2022-01-01 → 2022-12-31¥26.9bn
—segment totalrevenue intersegment2022-01-01 → 2022-12-31¥27m
—segment totalsegment profit2022-01-01 → 2022-12-31¥9.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,459
ItemContextValueUnit
Accrued expensesPrior1YearInstant_NonConsolidatedMember545595000JPY
Accrued expensesCurrentYearInstant_NonConsolidatedMember445245000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember2461923000JPY
Income taxes payableCurrentYearInstant_NonConsolidatedMember1080057000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember153924000JPY
Advances receivedCurrentYearInstant_NonConsolidatedMember823011000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember－JPY
Provision for bonusesCurrentYearInstant_NonConsolidatedMember582068000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember110345000JPY
Deposits receivedCurrentYearInstant_NonConsolidatedMember57355000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember500000000JPY
Short term loans payableCurrentYearInstant_NonConsolidatedMember－JPY
Current portion of long term loans payablePrior1YearInstant_NonConsolidatedMember2240000000JPY
Current portion of long term loans payableCurrentYearInstant_NonConsolidatedMember2640000000JPY
Other clPrior1YearInstant_NonConsolidatedMember－JPY
Other clCurrentYearInstant_NonConsolidatedMember126231000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember6837870000JPY
Current liabilitiesCurrentYearInstant_NonConsolidatedMember6093257000JPY
Long term loans payablePrior1YearInstant_NonConsolidatedMember18480000000JPY
Long term loans payableCurrentYearInstant_NonConsolidatedMember19740000000JPY
Deferred tax liabilitiesPrior1YearInstant_NonConsolidatedMember－JPY
Deferred tax liabilitiesCurrentYearInstant_NonConsolidatedMember1230347000JPY
Provision for share based remuneration nclPrior1YearInstant_NonConsolidatedMember102571000JPY
Provision for share based remuneration nclCurrentYearInstant_NonConsolidatedMember86307000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant_NonConsolidatedMember389248000JPY
Provision for share based remuneration for directors and other officers nclCurrentYearInstant_NonConsolidatedMember433490000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember18971819000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember21490144000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember25809689000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember27583401000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember3956738000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember3956738000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember3953020000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember3953020000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3953020000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember3953020000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember21841317000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember27658939000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember21841317000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember27658939000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-607334000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-1085546000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember29143740000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember34483150000JPY
Valuation difference on available for sale securitiesPrior1YearInstant_NonConsolidatedMember260035000JPY
Valuation difference on available for sale securitiesCurrentYearInstant_NonConsolidatedMember6069805000JPY
Valuation and translation adjustmentsPrior1YearInstant_NonConsolidatedMember260035000JPY
Valuation and translation adjustmentsCurrentYearInstant_NonConsolidatedMember6069805000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember21490000JPY
Subscription rights to sharesCurrentYearInstant_NonConsolidatedMember21490000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 18 of 22 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31mismatch
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31mismatch
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31mismatch
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31mismatch
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass